madman
Super Moderator
* Several other reversible male birth-control methods are now in the clinical trial pipeline as well. The furthest along is NES/T, a combination of testosterone and the progestin medication Nestorone. Applied daily as a gel to the shoulders and upper arms, it is absorbed into the bloodstream through the skin. Like the YCT-529 pill, the gel targets sperm production, but it does so by increasing the amount of circulating testosterone and progestin—hormones that tell the brain to halt the production process. Researchers have just completed a larger, longer phase 2 clinical trial of NES/T to show effectiveness and hope to start a phase 3 trial soon, says Page, who has been involved in the gel’s clinical research.
In this episode, host Rachel Feltman speaks with freelance science journalist Hannah Seo about a promising new development in male contraception: a hormone-free birth control pill that reversibly stops sperm production has just passed its first human safety trial. Seo explains how the drug works, what makes it different from hormone-based methods and where it stands in clinical development.
www.scientificamerican.com
www.nature.com
In this episode, host Rachel Feltman speaks with freelance science journalist Hannah Seo about a promising new development in male contraception: a hormone-free birth control pill that reversibly stops sperm production has just passed its first human safety trial. Seo explains how the drug works, what makes it different from hormone-based methods and where it stands in clinical development.
Male Birth Control Pill to Stop Sperm Production Passes Safety Test
A hormone-free pill, called YCT-529, that temporarily stops sperm production by blocking a vitamin A metabolite has just concluded its first safety trial in humans, getting a step closer to increasing male contraceptive options
Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529 - Communications Medicine
Mannowetz et al. evaluate the safety and tolerability of the small molecule YCT-529 and show that single doses of up to 180 mg were well tolerated in healthy male subjects of this Phase 1a clinical trial. YCT-529 is developed as a non-hormonal, oral male contraceptive pill with the intention to...
www.nature.com
